Document text
Principal Investigator: JAY A BERZOFSKY
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2021
Award: $1,303,369
Funding agency: National Cancer Institute
Due to the recent initiation of this project (April 2020) during the partial lab closure during the pandemic, progress on the objectives listed above has been limited, although 2 papers have been published already. In vitro studies in macaque bronchioalveolar lavage cells: So far, we have seen some effects in vitro on these cells of stimulating them with recombinant spike protein to affect expression of ACE2 and of interferons, that may play a role in infection. Little effect was seen on other cytokine or chemokine production. We recently published that S1 protein acts on macaque lung bronchoalveolar lavage cells to downregulate expression of the ACE2 receptor and also inhibit type I interferon production. Type I interferons have been shown to be essential for protection against SARS-CoV-2, and ACE2, besides being a receptor for spike protein, also protects the lung against respiratory viruses by cleaving angiotensin II, so downregulating these could worsen COVID-19. In vivo vaccine studies in macaques: Rhesus macaques have been primed IM with spike in different adjuvants and boosted systemically with spike in alum or mucosally intranasally with spike in nanoparticles with IL-15 and TLR ligand adjuvants. We have found and recently published that nanoparticles containing S1 spike protein delivered intranasally can boost macaques primed IM with S1 in alum and result in better protection against respiratory challenge with SARS-CoV-2 than can the IM vaccine alone even though the S1-binding and neutralizing antibody levels are lower. Other mechanisms must play a role and we have found correlations with mucosal IgA, dimeric IgA, and type I interferon production in the lung, and certain types of myeloid cells. We are now testing a mucosal nanoparticle boost with the B1.351 (South African) variant S1 protein to protect against this SARS-CoV-2 variant in macaques. Early results are promising for protection against variants. These studies suggest that a human intranasal nanoparticle COVID-19 vaccine given to people who had been previously immunized systemically with one of the approved vaccines, could improve protection against infection and reduce the risk of forward transmission to others by reducing intranasal virus, which is especially a problem with the new delta variant. In vivo studies in mice: ACE2-transgenic mice have been purchased despite delays, and are being bred. In wild type B6 mice, we have immunized with recombinant spike protein S1, S1+S2, or RBD in several different adjuvants to determine the best formulation. The best combination so far is IL-15 + ligands for TLR3 and 9, for both antibody and T cell responses. That work is in progress. The DNA vaccine with spike protein coupled to a chemokine is being constructed and that work is in progress. Human cell lines: We have received the immortalized human lung epithelial cell lines, that express ACE2, from John Minna at UTSW, as well as some of his non-small-cell lung cancer cell lines that also express ACE2. We have obtained an antibody to ACE2 to verify expression. Initial results show that omega-3 fatty acids and cholesterol differentially affect ACE2 expression on lung cancer cells as well as TMPRSS2 expression and may help explain how diet and obesity as well as lung cancer can affect susceptibility to SARS-CoV-2.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><Adjuvant><Affect><Alum Adjuvant><AngII><Angiotensin II><Animal Model><Animal Models and Related Studies><Antibodies><B-Cell Epitopes><B-Lymphocyte Epitopes><B.1.351><B.1.617.2><Binding><Bio-Informatics><Bioinformatics><Bronchioalveolar Lavage><Bronchoalveolar Lavage><Bronchopulmonary Lavage><COVID-19><COVID-19 S protein><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cancer cell line><Cell Body><Cell Line><CellLine><Cells><Chemotactic Cytokines><Cholesterol><Cleaved cell><CoV-2><CoV2><Coupled><DNA Vaccines><Delta variant><Dendritic Cells><Diet><Disease><Disorder><Dose><Electroporation><Engineering><Epithelial Cells><Epitheliasin Gene><FDA EUA><FDA Emergency Use Authorization><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Formulation><HIV vaccine><HIV/AIDS Vaccines><Homologous Chemotactic Cytokines><Human><Human Cell Line><IFN><IL-15><IL15><IL15 Protein><IgA><Immune><Immunes><Immunize><Immunoglobulin A><In Vitro><Industrialization><Infection><Infection prevention><Innate Immunity><Intercrines><Interferon Type I><Interferons><Interleukin-15><Interleukin-15 Precursor><Ligands><Lung><Lung Lavage><Lung Respiratory System><M mulatta><M. mulatta><MGC9721><Macaca><Macaca mulatta><Macaque><Malignant Tumor of the Lung><Malignant neoplasm of lung><Medical center><Methods><Mice><Mice Mammals><Modeling><Modern Man><Molecular Interaction><Morbidity><Morbidity - disease rate><Mucosa><Mucosal Immunity><Mucosal Tissue><Mucous Membrane><Murine><Mus><Myeloid Cells><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Naked DNA Vaccines><Nasal><Nasal Passages Nose><Native Immunity><Natural Immunity><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Non-Specific Immunity><Nonsmall Cell Lung Carcinoma><Nonspecific Immunity><Nose><Obesity><Omega-3 Fatty Acids><Omega-3 PUFA><Omega-3 Polyunsaturated Fatty Acid><Omega3><PRSS10><Paper><Play><Predisposition><Prevent infection><Production><Proteins><Publishing><Pulmonary Cancer><Pulmonary malignant Neoplasm><Receptor Protein><Recombinant DNA Vaccines><Recombinants><Respiratory Epithelium><Respiratory Mucosa><Respiratory System, Nose, Nasal Passages><Rhesus Macaque><Rhesus Monkey><Risk><Role><Route><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 B.1.617.2><SARS-CoV-2 S protein><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SIS cytokines><SIV Vaccines><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><South Africa variant><South African variant><Strains Cell Lines><Structure of respiratory epithelium><Susceptibility><T cell response><T-Cells><T-Lymphocyte><TLR3><TLR3 gene><TMPRSS2><TMPRSS2 gene><Testing><Texas><Toll-Like Receptor 3><Transgenic Mice><Transmission><Universities><Vaccines><Variant><Variation><Vascular Endothelial Cell><Veiled Cells><Viral><Viral Vaccines><Virus><Work><Wuhan coronavirus><adiposity><alum><aluminum sulfate><angiotensin converting enzyme 2><angiotensin converting enzyme II><base><bronchopulmonary lavage therapy><chemoattractant cytokine><chemokine><cleaved><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><corpulence><cultured cell line><cytokine><diets><dimer><electroporative delivery><emergency use authorization><experience><gene electrotransfer><hCoV19><human immunodeficiency virus vaccine><immunogenicity><immunopathology><improved><in vivo><lung cancer><lung cancer cell><model of animal><model organism><mucosal vaccine><n-3 Fatty Acids><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><non-human primate><nonhuman primate><nonsmall cell lung cancer><omega-3><pandemic><pandemic disease><pre-clinical study><preclinical study><pulmonary><receptor><receptor binding><receptor bound><respiratory><respiratory virus><response><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 B.1.617.2><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><simian immunodeficiency virus vaccines><social role><thymus derived lymphocyte><transmission process><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus><vaccine study><vaccine trial><viral transmission><virus transmission><ω-3 fatty acids>